METTL16 significantly enhances SOGA1 expression and mRNA stability via binding the “reader” protein insulin-like growth factor 2 mRNA binding protein 1 (IGF2BP1). SOGA1 is a direct downstream target of METTL16 and involved in METTL16 mediated glycolysis and CRC progression. The protein/RNA stability, RNA immunoprecipitation (RIP), Co-immunoprecipitation (Co-IP) and RNA pull-down assays were used to explore the potential molecular mechanisms. Glycolytic metabolism assays were used to verify the biological function of METTL16 and Suppressor of glucose by autophagy (SOGA1). The biological functions of METTL16 in CRC progression was analyzed in vivo and in vitro. The expression and prognostic value of METTL16 was evaluated using bioinformatics and immunohistochemistry (IHC) assays. This study explored the biological function of m6A methyltransferase METTL16 in glycolytic metabolism and revealed a new mechanism for the progression of Colorectal cancer (CRC). The role of N6-methyladenosine (m6A) modification in glycolysis is largely unknown. Glycolysis is the key hallmark of cancer and maintains malignant tumor initiation and progression.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |